Ceribell’s Strategic Expansion and Growth Potential with FDA Clearance for Clarity Algorithm

William Blair analyst Brandon Vazquez has maintained their bullish stance on CBLL stock, giving a Buy rating today.

Brandon Vazquez has given his Buy rating due to a combination of factors including the recent FDA 510(k) clearance for Ceribell’s Clarity algorithm, which is designed to detect seizures in preterm neonates and older patients. This clearance positions Ceribell as the first AI-powered EEG platform that covers all age groups, addressing a significant unmet need in neonatal intensive care units where many seizures go undetected without EEG monitoring.
Additionally, the clearance supports a favorable outlook for 2026, as it provides Ceribell with greater flexibility in launching their products, potentially allowing for simultaneous launches in neonatal and pediatric markets. This strategic move could enhance adoption in children’s hospitals and expand Ceribell’s presence in NICUs. Furthermore, the expansion into neonatal care adds a substantial market opportunity, reinforcing the company’s growth potential. With the stock trading at a relatively low multiple of 2026 sales, Vazquez sees this as an attractive entry point given the company’s strong growth catalysts.

In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $20.00 price target.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CBLL in relation to earlier this year.